stage

AIN
XX Pharma Breakthrough XX

XX Pharma Breakthrough XX

location_on Queensland ,  Australia

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

Implicit Bioscience is advancing IC14, a first-in-class antibody that switches off uncontrolled inflammation at its source, unlocking new treatments for ALS, acute respiratory distress, heart failure, and other diseases on the auto-immune scale

Highlights

  • First-in-Class global breakthrough in pharmaceticals most challenging space
  • Fully Established clinical safety in 8-year human and animal trial studies
  • World-class advisory panel, board and management team.
  • Substantial interest from 'Big Pharma' with several accessing our Data Room
  • Anticipated vastly shortened runway to commercialisation.

Overview

Target €2,800,000
Minimum €10,000
Investment Raised €2,300,000
Previous Rounds €5,700,000
Stage Pre-Startup/R&D
Investor Role Silent

Ask a question
Have a question?

Similar Projects

Technovate Business Pitch

Technovate Business Pitch

location_onNorth East, United States

In a day and age where technology is at the height of everything we do, Technovate specializes in providing IT/Audio/Visual/Automation systems for residential homeowners and commercial businesses. Our solutions are tailored specifically to each client

  • Creating Long Lasting relationships.
  • Generating and exceeding revenue targets YOY.
  • Ensuring to create systems that are user friendly, and beneficial.

€300,000

Total Required

€85,000

Min per Investor
Find out more
Marshall Papagos

Marshall Papagos

location_onGreece

Marshall Papagos is a newly designed flat-pack container based on composites and plastics, which is stealthy, lightweight, and addresses the defence and IMO Market. This new type revolutionises the logistics market in terms of cost and specification.

  • We have created from 2012 a mechanism of having EBITDA of 35%!
  • We have made a 1.1 return of Capital so far.
  • We have the strongest of Ties with MODs, NATO and have clients like DT!

€5,800,000

Total Required

€250,000

Min per Investor
Find out more
Ostoform

Ostoform

location_onMidlands, Ireland

Ostoform enables ostomy patients to live a life free from the worry of leaks and skin complications.

  • Product range developed and ready for commercial scale-up.
  • Distribution deals in place across 8 markets.
  • Reliable, recurring revenue streams in place.

€2,000,000

Total Required

€15,000

Min per Investor
Find out more
Loading…
Loading the web debug toolbar…
Attempt #